The role of race in heart failure therapy

Clyde W. Yancy

doi:10.1007/s11886-002-0054-0

The role of race in heart failure therapy

Clyde W. Yancy^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article

17 Scopus citations

Abstract

Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and b-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.

Original language	English (US)
Pages (from-to)	218-225
Number of pages	8
Journal	Current Cardiology Reports
Volume	4
Issue number	3
DOIs	https://doi.org/10.1007/s11886-002-0054-0
State	Published - Dec 1 2002

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11886-002-0054-0

Fingerprint Dive into the research topics of 'The role of race in heart failure therapy'. Together they form a unique fingerprint.

Cite this

Yancy, C. W. (2002). The role of race in heart failure therapy. Current Cardiology Reports, 4(3), 218-225. https://doi.org/10.1007/s11886-002-0054-0

@article{72fb9c971be3436e88b410c6d3a9894c,

title = "The role of race in heart failure therapy",

abstract = "Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and b-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.",

author = "Yancy, {Clyde W.}",

year = "2002",

month = dec,

day = "1",

doi = "10.1007/s11886-002-0054-0",

language = "English (US)",

volume = "4",

pages = "218--225",

journal = "Current Cardiology Reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "3",

}

TY - JOUR

T1 - The role of race in heart failure therapy

AU - Yancy, Clyde W.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and b-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.

AB - Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and b-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.

UR - http://www.scopus.com/inward/record.url?scp=0036581230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036581230&partnerID=8YFLogxK

U2 - 10.1007/s11886-002-0054-0

DO - 10.1007/s11886-002-0054-0

M3 - Article

C2 - 11960591

AN - SCOPUS:0036581230

VL - 4

SP - 218

EP - 225

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 3

ER -